Showing 5241-5250 of 7863 results for "".
- Risankizumab Maintains Efficacy and Safety in Pediatric Psoriasis Through 52 Weekshttps://practicaldermatology.com/news/risankizumab-maintains-efficacy-and-safety-in-pediatric-psoriasis-through-52-weeks/2485552/Risankizumab maintained or improved clinical response through one year in pediatric patients with moderate-to-severe plaque psoriasis, according to “Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis: Results Through 52 Weeks,” a poster by Nina Magnolo, MD, et al presented a
- Rezpegaldesleukin Demonstrates Broad Phase 2b Efficacy in Atopic Dermatitis and Asthmahttps://practicaldermatology.com/news/rezpegaldesleukin-demonstrates-broad-phase-2b-efficacy-in-atopic-dermatitis-and-asthma/2485541/Rezpegaldesleukin significantly improved disease severity, itch, and asthma-related symptoms in patients with moderate-to-severe atopic dermatitis, according to “Rezpegaldesleukin, Novel Treg-Inducing Therapy, Demonstrates Efficacy in Atopic Dermatitis and Asthma in a Phase 2b Trial,” a poster by
- Review: Seven HS PROMs Meet COSMIN Standards for Clinical Usehttps://practicaldermatology.com/news/review-seven-hs-proms-meet-cosmin-standards-for-clinical-use/2485535/A new systematic review and meta-analysis found seven clinically useful tools for capturing and analyzing hidradenitis suppurativa (HS)–specific patient-reported outcome measures (PROMs). The review, which included 26 studies a
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- OX40‑Targeted Therapy Among Dr. Hensin Tsao’s Highlights at Maui Derm Hawaii 2026https://practicaldermatology.com/news/ox40targeted-therapy-among-dr-hensin-tsaos-highlights-at-maui-derm-hawaii-2026/2485510/A novel immune pathway that may redefine atopic dermatitis (AD) treatment paradigms was among the highlights presented by Hensin Tsao, MD, in his conference-opening presentation at Maui Derm Hawaii 2026. Melanoma immunotherapy and various other topics were covered, but perhaps the most pot
- Study Flags Gaps in Readability, Representation in Monkeypox and HIV Resourceshttps://practicaldermatology.com/news/study-flags-gaps-in-readability-representation-in-mpox-and-hiv-resources/2485494/A new study reports that critical information on monkeypox (Mpox) and HIV remains largely inaccessible to the general public due to high reading levels and inconsistent cultural representation. Researchers publishing in the <
- Doxycycline and Minocycline Show Benefit in OLP Gingival Lesionshttps://practicaldermatology.com/news/doxycycline-and-minocycline-show-benefit-in-olp-gingival-lesions/2485468/A retrospective analysis suggests doxycycline and minocycline may offer an effective systemic option for patients with inflammatory oral lichen planus (OLP) involving the gingiva who fail to respond to topical agents. Study res
- Arcutis Ends Kowa Promotional Partnership, Assumes Control of ZORYVE Promotionshttps://practicaldermatology.com/news/arcutis-ends-kowa-deal-assumes-full-control-of-zoryve-outreach/2485454/Arcutis Biotherapeutics has terminated its co-promotion agreement with Kowa Pharmaceuticals America, Inc. for ZORYVE® (roflumilast), effective January 23, 2026, according to a press relase from the company. Under the prior arran
- RE-UNITE-PN Launched to Evaluate Nemolizumab in Prurigo Nodularishttps://practicaldermatology.com/news/re-unite-pn-launched-to-evaluate-nemolizumab-in-prurigo-nodularis/2485449/A new international, non-interventional study aims to provide critical real-world data on nemolizumab’s performance in patients with moderate-to-severe prurigo nodularis (PN). The RE-UNITE-PN study (NCT06988618), sponsored by Galderma, is designed to complement pivo
- Sclerotic cGVHD Patients Show Higher Risk for Outcome Reporting Mismatchhttps://practicaldermatology.com/news/patient-reported-cgvhd-worsening-linked-to-mortality-in-sclerotic-disease/2485447/A new longitudinal cohort study published in JAMA Dermatology showed differences in frequency and importance of discordance between clinician-reported and patient-reported outcomes in cutaneous chronic graft-vs-host disease (cG